Compare CLMB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | ALT |
|---|---|---|
| Founded | 1982 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.6M | 421.5M |
| IPO Year | 1996 | 2005 |
| Metric | CLMB | ALT |
|---|---|---|
| Price | $22.64 | $2.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $80.00 | $17.67 |
| AVG Volume (30 Days) | 128.7K | ★ 2.6M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | 14.29 | ★ 25.37 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $652,517,000.00 | $41,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $5.83 | N/A |
| P/E Ratio | $128.89 | ★ N/A |
| Revenue Growth | 40.14 | ★ 105.00 |
| 52 Week Low | $15.25 | $2.56 |
| 52 Week High | $145.00 | $7.73 |
| Indicator | CLMB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 49.85 | 36.34 |
| Support Level | $18.97 | $2.56 |
| Resistance Level | $23.60 | $4.19 |
| Average True Range (ATR) | 1.17 | 0.12 |
| MACD | 0.50 | -0.03 |
| Stochastic Oscillator | 50.86 | 9.79 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.